Clinical trial • Other

MORPHINE SULFATE for Postoperative pain following major laparoscopic abdominal surgery

Clinical trial of MORPHINE SULFATE for Postoperative pain following major laparoscopic abdominal surgery.

Overview

Trial Therapeutic Area
Other
Trial Disease
Postoperative pain following major laparoscopic abdominal surgery
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
12-09-2025
First CTIS Authorization Date
22-12-2025

Trial design

Randomised, comparator: tramadol (tramadol 100 mg/ml oral drops, solution). test/other arm: morphine (morfinesulfaat sandoz 10 mg tablets and morphine sulfate 10 mg/ml solution for injection). dose and schedule not specified in the ctis record.-controlled trial across 1 site in France.

Randomised
Yes
Comparator
Comparator: Tramadol (Tramadol 100 mg/ml oral drops, solution). Test/other arm: Morphine (Morfinesulfaat Sandoz 10 mg tablets and Morphine Sulfate 10 mg/ml Solution for Injection). Dose and schedule not specified in the CTIS record.
Target Sample Size
140
Trial Duration For Participant
90

Eligibility

Recruits 140 Vulnerable populations are not selected for inclusion. Patients under legal guardianship, legal protection, or deprived of liberty are explicitly excluded. Consent must be signed by the patient (adults only, Age ≥18). No paediatric assent procedures; study uses adult ICF documents..

Pregnancy Exclusion
Pregnant or breastfeeding women
Vulnerable Population
Vulnerable populations are not selected for inclusion. Patients under legal guardianship, legal protection, or deprived of liberty are explicitly excluded. Consent must be signed by the patient (adults only, Age ≥18). No paediatric assent procedures; study uses adult ICF documents.

Inclusion criteria

  • {"criterion_text":"- Age ≥18 years\n- Scheduled laparoscopic abdominal surgery with an expected operative duration of 2 hours or more\n- Affiliation to the national health insurance system\n- Signed informed consent to participate in the study"}

Exclusion criteria

  • {"criterion_text":"- Allergy or intolerance to any of the following medications: paracetamol, nefopam, ketoprofen, tramadol, morphine, sufentanil, lidocaine, propofol, ketamine, dexamethasone, or droperidol\n- Patient unable to self-assess pain using a numerical rating scale (0–10) (e.g., due to language barrier)\n- Pregnant or breastfeeding women\n- Patient under legal guardianship, legal protection, or deprived of liberty\n- Contraindication to any of these medications (refer to the Summary of Product Characteristics): paracetamol, ketoprofen, nefopam, tramadol, morphine, sufentanil, lidocaine, propofol, ketamine, dexamethasone, or droperidol\n- Chronic use of monoamine oxidase inhibitors or CYP2D6 inhibitors\n- Chronic preoperative use of level 2 or 3 analgesics\n- Outpatient surgery\n- Surgery requiring postoperative admission to an intensive care unit (ICU)\n- Patient on long-term oxygen therapy\n- Patient with psychiatric disorders\n- Patient with neurodegenerative diseases"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The primary endpoint is the multidimensional score validated in French assessing postoperative patient recovery: the QoR-15 (Quality of Recovery-15) score at 24 hours after surgery.","definition_or_measurement_approach":"QoR-15 (Quality of Recovery-15) score measured at 24 hours postoperatively (French-validated questionnaire)."}

Secondary endpoints

  • {"endpoint_text":"- QoR-15 questionnaire scores at 48 and 72 hours","definition_or_measurement_approach":"QoR-15 score measured at 48 and 72 hours postoperatively."}
  • {"endpoint_text":"- Mean postoperative pain NRS (0–10) scores in the Post-Anesthesia Care Unit (PACU), and at 24, 48, and 72 hours","definition_or_measurement_approach":"Pain intensity assessed on an 11-point Numerical Rating Scale (NRS 0–10) in PACU and at 24, 48, 72 hours."}
  • {"endpoint_text":"- Opioid consumption expressed in oral morphine equivalent at 24 and 72 hours postoperatively","definition_or_measurement_approach":"Total opioid consumption converted to oral morphine equivalents at 24 and 72 hours postoperatively."}
  • {"endpoint_text":"- Analgesic efficacy after opioid administration, assessed by NRS (0–10) two hours post opioid administration","definition_or_measurement_approach":"NRS (0–10) assessed 2 hours after opioid administration to evaluate analgesic efficacy."}
  • {"endpoint_text":"- Length of stay in the PACU (minutes) and total postoperative hospital stay (days)","definition_or_measurement_approach":"Duration in PACU measured in minutes; total postoperative hospital length of stay measured in days."}
  • {"endpoint_text":"- Occurrence of the following adverse effects after opioid use: nausea/vomiting, ileus, hypoxemia, pruritus, confusion (assessed by CAM tool)","definition_or_measurement_approach":"Incidence of listed opioid-related adverse events within 72 hours postoperatively; confusion assessed using the CAM tool."}
  • {"endpoint_text":"- Pain management satisfaction score, evaluated on a numerical scale from 0 to 10 (0 = total dissatisfaction, 10 = total satisfaction) at hospital discharge","definition_or_measurement_approach":"Patient-reported satisfaction score (0–10) at hospital discharge."}
  • {"endpoint_text":"- Number of patients consuming opioids daily at 1 and 3 months post-discharge","definition_or_measurement_approach":"Count of patients reporting daily opioid consumption at 1 and 3 months after discharge."}
  • {"endpoint_text":"- Misuse risk assessment using the POMI-5F scale","definition_or_measurement_approach":"Risk of misuse evaluated with the POMI-5F questionnaire."}
  • {"endpoint_text":"- Presence of chronic post-surgical pain at 3 months after surgery","definition_or_measurement_approach":"Assessment of presence of chronic post-surgical pain at 3 months post-surgery."}

Recruitment

Planned Sample Size
140
Recruitment Window Months
31
Consent Approach
Signed informed consent must be provided by the patient (adult). Subject information and ICF Adults (L1_SIS and ICF Adults) are provided; study enrols adults (Age ≥18). Documentation includes French-language translations of protocol materials.

Geography

Total Number Of Sites
1
Total Number Of Participants
140

France

Earliest CTIS Part Ii Submission Date
18-11-2025
Latest Decision Or Authorization Date
22-12-2025
Processing Time Days
34
Number Of Sites
1
Number Of Participants
140

Sites

Site Name
Centre Hospitalier Universitaire Amiens Picardie
Department Name
Anesthesia
Principal Investigator Name
Paul TARPIN
Principal Investigator Email
tarpin.paul@chu-amiens.fr
Contact Person Name
Paul TARPIN
Contact Person Email
tarpin.paul@chu-amiens.fr
Number Of Participants
140

Sponsor

Primary sponsor

Full Name
Centre Hospitalier Universitaire Amiens Picardie
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
Morphine Sulfate 10mg /ml Solution for Injection
Active Substance
MORPHINE SULFATE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS ADMINISTRATION
Route
INTRAVENOUS ADMINISTRATION
Authorisation Status
Authorised
Maximum Dose
60 mg per day
Investigational Product Name
Morfinesulfaat Sandoz 10 mg, tabletten
Active Substance
MORPHINE SULFATE
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
ORAL USE
Authorisation Status
Authorised
Maximum Dose
60 mg per day
Investigational Product Name
Tramadol 100 mg/ml oral drops, solution.
Active Substance
TRAMADOL
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
ORAL USE
Authorisation Status
Authorised
Maximum Dose
400 mg per day
Combination Treatment
Yes

Related trials

Other published trials that may interest you.